People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

It was approved... The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...